Endomyocardial fibrosis (EMF) is a disease characterized by excessive accumulation of fibrous tissue in the endocardium and myocardium, which leads to dysfunction of the heart and its structural changes. EMF mainly affects tropical regions, but in recent years there has been an increase in cases in other countries due to population migration and environmental changes. The pathology is most often diagnosed in young people and especially in women, which makes it a relevant topic for study in the field of cardiology. Clinicians are faced with an increasing number of cases year after year when patients seek symptoms associated with heart failure, such as shortness of breath, fatigue, and swelling of the extremities. This condition requires a specialized approach to diagnosis and treatment.
History of the disease and interesting historical facts
Endomyocardial fibrosis was first described in the 1970s, when scientists began systematically studying cardiovascular disease in tropical regions. The earliest cases were reported in equatorial Africa, and clusters have since been documented in other tropical countries, including Brazil and Indonesia. In the 1980s, a video of the condition appeared in scientific studies, spurring further study of EMF. Interestingly, its prevalence in some regions may be related to specific diets and exposure to exogenous toxins, such as aflatoxins. Studies have also linked EMF to certain infectious diseases, such as viral fever.
Epidemiology
According to statistics, the incidence of endomyocardial fibrosis in tropical regions can reach 1-2 cases per 1000 inhabitants. Studies conducted in certain areas of Africa show that the incidence in the adult population varies significantly, and can reach 5% in some isolated communities. In recent years, EMF has been increasingly recorded in countries with a temperate climate, which may be due to migration and changing climatic conditions. For example, in South America and Southeast Asia, the incidence was 0.5-1%. Ongoing epidemiological studies emphasize the importance of monitoring and controlling this disease to reduce its impact on public health.
Genetic predisposition to this disease
Although endomyocardial fibrosis is most often considered a nutritional and environmental pathology, a significant role of genetic factors has been established in some cases. Several studies have shown that mutations in certain genes, such as MYH7 and TNNT2, may increase the risk of developing EMF. These mutations are associated with impaired cardiomyocyte function and, therefore, lead to fibrotic changes in the myocardium. Familial cases of the disease are also observed, indicating a possible hereditary predisposition. It is important to note that the pathogenetic mechanisms require further study, and genetic predisposition may vary depending on the geographic region.
Risk factors for the development of this disease
Risk factors that contribute to the development of endomyocardial fibrosis can be divided into physical, chemical and infectious. Physical factors include:
- Long-term exposure to high temperatures.
- Lack of moisture in the climate.
- Physical activity in conditions of insufficient hydration.
Chemical factors include:
- Consumption of foods containing aflatoxins.
- Exposure to toxins such as heavy metals and pesticides.
Infectious factors:
- Viral infections.
- Pathogenic bacteria interacting with the heart muscle.
All of the listed factors can contribute to the pathogenesis of EMF and require a comprehensive approach to prevention.
Diagnosis of this disease
Diagnosis of endomyocardial fibrosis is based on clinical data, laboratory and instrumental studies. The main symptoms include:
- Shortness of breath.
- Swelling of the extremities.
- Fatigue and weakness.
Laboratory tests may include blood tests for cardiac markers such as troponin and natriuretic peptides. Radiological tests such as echocardiography and cardiac magnetic resonance imaging can visualize changes in myocardial structure and detect fibrotic lesions. Other diagnostic tests, including myocardial biopsy, can confirm the presence of fibrotic changes, which can help differentiate the cause from other cardiac diseases.
Treatment
Treatment of patients with endomyocardial fibrosis is based on an individual approach, which includes both conservative and surgical methods. General treatment is aimed at reducing symptoms and improving quality of life, including regimen and diet. Pharmacological treatment includes the administration of diuretics, beta-blockers and anticoagulants, which allows for control of the cardiovascular system and prevention of thrombus formation. In some cases, surgical treatment is necessary, including heart transplantation or correction of associated valvular pathologies. Other methods, such as rehabilitation and supportive therapy, also play an important role in long-term disease management.
List of medications used to treat this disease
The main drugs used in the treatment of endomyocardial fibrosis include:
- Diuretics (furosemide).
- Beta-blockers (metoprolol).
- Anticoagulants (warfarin).
- ACE inhibitors (enalapril).
These drugs are aimed at reducing symptoms and reducing the risk of complications associated with the disease.
Disease monitoring
Monitoring of patients with endomyocardial fibrosis involves regular examinations and assessment of cardiac function. Control steps include:
- Echocardiographic studies to assess heart function.
- Laboratory tests to monitor cardiac markers.
- Assessment of the patient's general condition and symptoms.
The prognosis for the disease can vary. Some patients can live for many years with timely treatment, while others may experience serious complications such as heart failure or arrhythmia.
Age-related features of the disease
Endomyocardial fibrosis may present differently depending on the patient's age. In younger people, the disease is most often associated with acute symptoms and more rapid progression. In older patients, EMF usually presents with less severe symptoms, but the risk of complications and heart failure increases significantly. It is important to consider age-related changes in cardiac structure and function when diagnosing and treating this disease.
Questions and Answers
- What is endomyocardial fibrosis? Endomyocardial fibrosis is a disease that results in excessive accumulation of fibrous tissue in the heart muscle.
- What are the main symptoms of EMF? The main symptoms include shortness of breath, swelling and fatigue.
- How is EMF diagnosed? Diagnostics includes clinical examination, laboratory tests, echocardiography and other instrumental methods.
- What treatment methods exist? Treatment may be pharmacological, surgical, or supportive depending on the severity of the disease.
- What is the prognosis for endomyocardial fibrosis? The prognosis varies depending on the speed of diagnosis and the quality of treatment, and some patients may live longer if treated promptly.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends the following for the prevention and management of endomyocardial fibrosis:
- Get regular medical check-ups, especially if you have risk factors.
- Eat a balanced diet and avoid foods containing aflatoxins.
- Engage in moderate physical activity and monitor fluid levels in the body.
- Take care of your psycho-emotional state, as stress can worsen the symptoms of the disease.
These simple tips will help not only in prevention, but also in monitoring your health if you are at risk of developing endomyocardial fibrosis.
